Optipeg-A 135 mcg/0.5 ml (SC Injection)

0.5 ml pre-filled syringe: ৳ 8,800.00

Medicine Details

Category Details
Generic Peginterferon alfa 2a pegylated interferon alfa 2a
Company Incepta pharmaceuticals ltd
Also available as
Optipeg a 180 mcg injection

Product Title

  • Optipeg-A

Categories

  • Medicine
  • Hepatitis C treatment
  • Hepatitis B treatment

Description

  • Indicated for the treatment of adults with chronic hepatitis C (CHC) virus infection
  • Indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B
  • Peginterferon alfa-2a are interferon proteins bound to polyethylene glycol (PEG) molecules
  • Has antiviral, antiproliferative, and immune-regulating activity
  • Recommended dose of 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thigh for Chronic hepatitis C
  • Recommended dose of 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thigh for Chronic hepatitis B
  • Genotype 1 & 4: dual therapy with Celbarin and weight-based dosage
  • Genotype 2 & 3: dual therapy with Celbarin and different duration
  • Interacts with drugs metabolized by CYP1A2, methadone, nucleoside analogues, zidovudine, and azathioprine
  • Contraindicated in cases of hypersensitivity to any component, autoimmune hepatitis, hepatic decompensation, and in neonate or infants
  • May cause side effects such as depression, flu-like symptoms, gastrointestinal issues, musculoskeletal problems, neurological issues, psychiatric reactions, injection site reactions, hair loss, and endocrine disorders
  • Pregnancy Category C: Recommended for use in women of childbearing potential only when using effective contraception
  • Should be used with caution in patients who have failed alpha interferon treatment, liver or other organ transplant recipients, hepatitis B patients coinfected with HCV or HIV, and in patients with baseline risk of severe anemia
  • Dose modifications required for patients with hepatic impairment and renal impairment
  • Limited experiences of overdose, no serious reactions attributed to overdose

Dosage and Administration

  • Peg interferon dose: 180 mcg once weekly for 48 weeks
  • Subcutaneous administration on abdomen or thigh
  • Different dosing for Genotype 1 & 4 and Genotype 2 & 3

Interaction

  • Interacts with drugs metabolized by CYP1A2, methadone, nucleoside analogues, zidovudine, and azathioprine

Contraindications

  • Hypersensitivity to any component
  • Autoimmune hepatitis
  • Hepatic decompensation in cirrhotic patients
  • Neonate or infants

Side Effects

  • Depression, flu like symptoms, gastrointestinal issues, musculoskeletal problems, neurological issues, psychiatric reactions, injection site reactions, hair loss, endocrine disorders

Pregnancy and Lactation

  • Pregnancy Category C: Use with effective contraception
  • It is not known whether the components are excreted in human milk

Precautions and Warnings

  • Use with caution in specific patient groups
  • Dose modifications required for patients with hepatic impairment and renal impairment

Use in Special Populations

  • Dose modifications required for patients with hepatic impairment and renal impairment

Overdose Effects

  • Limited experiences of overdose
  • No serious reactions attributed to overdose

Therapeutic Class

  • Hepatic viral infections (Hepatitis B)
  • Hepatic viral infections (Hepatitis C)

Storage Conditions

  • Store in refrigerator at 2-8°C
  • Protect from light

Related Brands